摘要
文章研究的目的在于探讨幽门螺杆菌(Helicobacter pylori,HP)与疣状胃炎的关系以及国产胶体铋剂(丽珠得乐)与进口胶体铋剂(De-Nol)对疣状胃炎的治疗效果。经内镜检查诊断的疣状胃炎病人40例,全部做HP检查(包括尿素酶试验,细菌培养,Warthin-starry银染色病理组织学检查)。病人随机分为3个治疗组:De-Nol组;丽珠得乐组;雷尼替丁组。De-Nol和丽珠得乐的用法分别为120mg每日4次和110mg每日4次,雷尼替丁为150mg,每日2次,均为口服用药,疗程8周。结果:疣状胃炎中,HP检出率为92.5％(37/40),3组药对HP的清除率分别为86.7％,83.3％和10.0％。疣状隆起或糜烂消失率分别为75.0％,69.2％和36.5％;胃窦炎改善分别为87.5％,84.6％和36.5％;活动性炎症消失率分别为78.6％,72.7％及30.0％。研究结果表明:疣状胃炎与HP有关,HP可能是疣状胃炎的重要病因之一,并且提示胶体铋剂治疗疣状胃炎效果明显优于雷尼替丁,国产的与进口的胶体铋剂治疗疣状胃炎效果相同。
The relationship between verrucous gastritis and H. pylori has been studied, as well as the therapeutic effects of colloidal bismuth subcitrate (CBS) on verrucous gastritis. Forty patients with endoscopically verified verrucous gastritis were randomized to receive 120mg De-Nol (CBS, Netherlands) four times daily, 110mg De-Le(CBS, Zhuhai, China)four times daily or 150mg Ranitidine twice daily for eight weeks. Before treatment, 37 of the patients were H. pylori positive, histology showed serious antral gastritis in all patients and 35 of the patients had active gastritis. After eight weeks of treatment with De-Nol, De-Le and Ranitidine, the number of cases with H. pylori infection was reduced by 86.7%, 83.3% and 10.0% respectively, the number of cases with verrucous eminence was reduced by 75.6 %, 69.2% and 36.5%, antral gastritis improved in 87.5 %, 84.6 % and 36.5% of the patients, and active antral gastritis improved in 78.6%, 72.7% and 30.0% of the patients. The research indicates that H. pylori treatment was associated with significant improvements in gastritis, and that De-Nol and De-Le were almost equally effective in the treatment of verrucous gastritis and superior to Ranitidine. This study emphasized the pathogenetic role of H. pylori in verrucous gastritis.
出处
《中国内镜杂志》
CSCD
1997年第1期14-15,18,共3页
China Journal of Endoscopy
关键词
疣状胃炎
幽门螺杆菌
胶体饿剂
雷尼替丁
胃炎
Verrusous gastritis
Helicobacter pylori
Colloidal bismuth subcitrate
Ranitidine
